Boehringer Ingelheim and Zealand Pharma have kicked ... consultant in metabolic medicine at University College in Dublin in Ireland, who was the principal investigator of the phase 2 trial.

Commenting on the Jardiance decision, Dr Christoph Zehendner, medical director of Boehringer Ingelheim UK and Ireland, noted that HF with mildly reduced and preserved ejection fraction represents ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

In a powerful demonstration of high-level support, the World Health Organization (WHO) today received nearly US$ 700 million ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...

Ireland's rich culture, enchanting green landscapes and friendly locals are just a few reasons why so many travelers make the journey to this island country. But with so many cities, charming ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Join Steve Mason and John Ireland every day from 12p.m. - 3 p.m. PT. The longest running duo in L.A., Mason & Ireland set the standard for sports talk radio. As Travis & Kelvin continue to look ...